Progyny Q2 2026 earnings: Margin expansion lifts profit faster than revenue

Progyny (Nasdaq: PGNY) reported Q2 2026 revenue of $350.5 million, up 5.3% year over year, and diluted EPS of $0.34, compared with $0.19 in Q2 2025. Gross-margin expansion and lower stock-based compensation helped net income grow much faster than revenue, although quarterly operating cash flow declined to $50.4 million because of working-capital timing.

Core earnings data

Reported revenue growth continued to reflect the loss of a large client that contributed $17.2 million in Q2 2025 but nothing in the latest quarter. Excluding that prior-year contribution, Progyny said revenue increased 11.0%.

Profit growth was substantially faster than revenue growth. Gross profit rose 13%, while operating expenses declined, lifting operating income and net income sharply.

Adjusted EPS and adjusted EBITDA are non-GAAP measures that exclude items including stock-based compensation.

Business and operating metrics

Fertility benefit services generated nearly all of the incremental segment revenue, growing 7.6%, while pharmacy benefit services increased only 1.2%. Client and member counts also rose, but ART cycles were nearly unchanged from the prior-year quarter.

Average membership includes approximately 300,000 members from one client whose benefit design excludes them from utilization calculations. The 2025 utilization figures also exclude activity covered by the former large client’s transition arrangement.

Lower stock compensation amplified GAAP profit growth

Progyny attributed gross-margin expansion to care-management efficiencies and lower stock-based compensation. Total stock-based compensation declined to $20.5 million from $32.4 million, helping reported operating expenses fall to $49.3 million from $54.6 million.

The difference between GAAP and non-GAAP growth is important. GAAP gross margin expanded by about 1.8 percentage points, but gross margin excluding stock-based compensation increased by about 0.6 percentage points, to 27.2% from 26.6%. Similarly, net income rose about 64%, while adjusted EBITDA increased 7.2% because planned platform investments absorbed part of the higher gross profit.

A lower diluted share count also helped EPS grow faster than net income. Weighted-average diluted shares declined to 82.1 million from 89.6 million.

Cash flow, balance sheet and repurchases

Quarterly operating cash flow declined to $50.4 million despite higher net income, with Progyny attributing the difference to the timing of working-capital items. Trailing-12-month operating cash flow was broadly stable at $201.2 million, compared with $202.0 million a year earlier.

Progyny ended June with $236.9 million in cash, cash equivalents and marketable securities, $272.9 million in working capital and no debt. Its $200 million revolving credit facility remained undrawn.

The company repurchased nearly 1.2 million shares for $31.5 million during Q2 under its May 2026 program. It had repurchased 2 million shares under that authorization through the reporting date, leaving approximately $142.5 million available. These repurchases should be viewed as a capital-allocation action rather than evidence that management considers the shares undervalued, as no such statement was provided.

Earnings guidance

Management’s outlook incorporates a slightly more pronounced seasonal slowdown in member activity during the peak summer period. Its assumptions then call for September engagement to return to levels consistent with the first half of 2026.

Excluding the former large client’s $48.5 million of transition-related revenue in 2025, full-year revenue growth is projected at 9.7% to 11.7%. The source did not provide a prior guidance range for comparison.

Management commentary

CEO Pete Anevski said member engagement tracked toward the high end of the company’s expectations during Q2. He also reported favorable selling-season momentum, with new covered lives and the expected contribution from early commitments running meaningfully ahead of the same point last year.

On renewals, management said commitments received so far had removed the vast majority of retention risk associated with Progyny’s largest accounts. CFO Mark Livingston emphasized that operating cash generation continues to give the company room to invest in its platform while repurchasing shares.

Recent insider transactions

The provided six-month summary lists 392,152 shares acquired across 15 transactions and 49,013 shares sold across 12 transactions, resulting in net acquisitions of 343,139 shares. Because the acquisition category may include stock grants and derivative exercises, it should not be interpreted as 392,152 shares of open-market buying.

The 10 most recent reported transactions consisted of eight sales and two derivative-security exercises. These records are presented objectively and do not establish insiders’ views on the company’s outlook.

Risks investors should monitor

• Summer engagement seasonality: Q3 guidance assumes a somewhat more pronounced seasonal reduction in member activity before engagement recovers in September.
• Large-client concentration: The loss of one client removed $17.2 million from the Q2 comparison and continues to affect reported full-year growth rates.
• Investment-related margin pressure: Planned spending on platform features and functionality limited adjusted EBITDA growth despite higher gross profit.
• Cash-flow timing: Operating cash flow declined even as net income increased, making working-capital movements an important factor to monitor.
• Uneven service-line growth: Fertility benefit revenue increased 7.6%, but pharmacy revenue grew only 1.2% and ART cycles were approximately flat.

Summary

Progyny’s Q2 2026 results combined moderate reported revenue growth with substantially faster GAAP profit growth, supported by care-management efficiencies, lower stock-based compensation and a reduced diluted share count. Underlying revenue growth was higher after excluding the former large client, while fertility services outperformed pharmacy services. The main follow-up points are Q3 summer engagement, selling-season commitments and renewals, the effect of platform investment on adjusted margins, and whether operating cash flow keeps pace with earnings.